Now showing items 1-2 of 2

    • 12 new susceptibility loci for prostate cancer identified by genome-wide association study in Japanese population. 

      Takata, R; Takahashi, A; Fujita, M; Momozawa, Y; Saunders, EJ; Yamada, H; Maejima, K; Nakano, K; Nishida, Y; Hishida, A; Matsuo, K; Wakai, K; Yamaji, T; Sawada, N; Iwasaki, M; Tsugane, S; Sasaki, M; Shimizu, A; Tanno, K; Minegishi, N; Suzuki, K; Matsuda, K; Kubo, M; Inazawa, J; Egawa, S; Haiman, CA; Ogawa, O; Obara, W; Kamatani, Y; Akamatsu, S; Nakagawa, H (2019-09-27)
      Genome-wide association studies (GWAS) have identified ~170 genetic loci associated with prostate cancer (PCa) risk, but most of them were identified in European populations. We here performed a GWAS and replication study ...
    • First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors. 

      Shimomura, A; Yamamoto, N; Kondo, S; Fujiwara, Y; Suzuki, S; Yanagitani, N; Horiike, A; Kitazono, S; Ohyanagi, F; Doi, T; Kuboki, Y; Kawazoe, A; Shitara, K; Ohno, I; Banerji, U; Sundar, R; Ohkubo, S; Calleja, EM; Nishio, M (2019-03)
      HSP90 is involved in stability and function of cancer-related proteins. This study was conducted to define the MTD, safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor efficacy of TAS-116, a novel class, ...